David Bredt, Chief Scientific Officer at Rapport Therapeutics, Inc. (RAPP), sold 8,500 shares at $14.98 ($127K) on 2025-08-15, disclosed to the SEC on 2025-08-18.
Scheduled sale ($127k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.98 | 8,300 | $124K | 97.5% |
| 2 | $15.79 | 200 | $3K | 2.5% |
| Total | $15.00 avg | 8,500 | $127K | 100% |
| Filing → |
| RAPP | SELL | 2026-01-05 | $395K | — | Filing → |
| RAPP | SELL | 2025-12-16 | $486K | — | Filing → |
| RAPP | SELL | 2025-11-18 | $428K | — | Filing → |